Cargando…
Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial
OBJECTIVE: We evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS). METHODS: In this double-blind phase 2b trial, patients with AIS aged 18–80 years with NIH Stroke Scale scores of 5–23 from 53 US and European sites were randomized 1:1:1...
Autores principales: | Elkind, Mitchell S.V., Veltkamp, Roland, Montaner, Joan, Johnston, S. Claiborne, Singhal, Aneesh B., Becker, Kyra, Lansberg, Maarten G., Tang, Weihua, Kasliwal, Rachna, Elkins, Jacob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668547/ https://www.ncbi.nlm.nih.gov/pubmed/32591475 http://dx.doi.org/10.1212/WNL.0000000000010038 |
Ejemplares similares
-
Repetitive TMS does not improve cognition in patients with TBI: A randomized double-blind trial
por: Neville, Iuri Santana, et al.
Publicado: (2019) -
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
por: Lochmüller, Hanns, et al.
Publicado: (2019) -
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
por: Meyer, Pierre-François, et al.
Publicado: (2019) -
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020) -
Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies
por: Todd, Joshua J., et al.
Publicado: (2020)